# Study of Adjunctive or Monotherapy Rapastinel Treatment in Patients With Major Depressive Disorder (MDD)

> **NCT03668600** · PHASE3 · TERMINATED · sponsor: **Naurex, Inc, an affiliate of Allergan plc** · enrollment: 230 (actual)

## Conditions studied

- Depressive Disorder, Major

## Interventions

- **DRUG:** Rapastinel

## Key facts

- **NCT ID:** NCT03668600
- **Lead sponsor:** Naurex, Inc, an affiliate of Allergan plc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-08-23
- **Primary completion:** 2019-07-03
- **Final completion:** 2019-07-03
- **Target enrollment:** 230 (ACTUAL)
- **Why stopped:** Business decision to stop the program
- **Last updated:** 2020-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03668600

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03668600, "Study of Adjunctive or Monotherapy Rapastinel Treatment in Patients With Major Depressive Disorder (MDD)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03668600. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*